All In Biotech

Drug Trial Radar · NCT07792928

A Study of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) After Single Administration in Healthy Adult Participants.

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Oct 14, 2026

Primary completion

Nov 10, 2026

Study completion Nov 10, 2026

Sponsor

Sponsor type
Industry
Collaborators
Emerald Clinical Trials Pty Ltd
First posted
Aug 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this intervention study is to assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Participants. The main parameters it aims to answer are: Does a single dose of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in healthy participants impact the Safety, Tolerability, Pharmacokinetics, and Immunogenicity profiles? This study will be a randomized, double blind, placebo-controlled study.

Conditions

  • Psoriasis

Interventions

  • HCXT-2001 TabletsDrug

    Two tablets taken orally in a fasted state

  • PlaceboDrug

    Two tablets taken orally in a fasted state

  • HCXT-2001 Tablets(A)Drug

    Two tablets taken orally in a fasted state

  • HCXT-2001 TabletsDrug

    One tablet taken orally in a fasted state

  • PlaceboDrug

    One tablet taken orally in a fasted state

  • HCXT-2001 Tablets(A)Drug

    One tablet taken orally in a fasted state

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with AEs,SEAs, with abnormal - vital signs,physcial examinations,clinical laboratory results ,12-lead ECGs and stool routine testsTime frame: Day 1 to Day 50

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • New Zealand Clinical Research Christchurch

    Christchurch, New Zealand

  • New Zealand Clinical Research Auckland

    Grafton, New Zealand

  • Momentum Clinical Research (MCR)

    Takapuna, Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.